Immune Cell Dysregulation in Gut Diseases: Mechanisms, Clinical Correlates, and Therapeutic Implications in IBD, CRC, and IBS

Abstract

Immune homeostasis in the intestinal tract requires precise coordination among epithelial barriers, innate sentinels, adaptive lymphocytes, stromal elements, and the microbiota. Disruption of this equilibrium—by genetic predisposition, environmental triggers, microbial dysbiosis, or barrier injury—can drive immune cell dysregulation and manifest as distinct gut diseases with overlapping biology: inflammatory bowel disease (IBD), colorectal cancer (CRC), and irritable bowel syndrome (IBS). In IBD, hyperactive cytokine circuits (e.g., TNF, IL-23/Th17), maladaptive innate lymphoid cell (ILC) responses, and defects in microbial sensing and autophagy prime chronic, relapsing inflammation and barrier failure, with robust clinical trial evidence supporting cytokine, integrin, JAK, and S1P-receptor–targeted therapies. In CRC, chronic inflammation and a reprogrammed tumor immune microenvironment (TIME)—enriched for immunosuppressive myeloid cells, Tregs, and sometimes microbiota such as Fusobacterium nucleatum—shape tumorigenesis, progression, and response to immunotherapy; dMMR/MSI-H tumors are exquisitely responsive to PD-1 blockade. In IBS, many patients exhibit low-grade mucosal immune activation with mast cell–neuronal cross-talk and post-infectious immune footprints that contribute to visceral hypersensitivity, despite the absence of macroscopic inflammation. This review synthesizes fundamental mechanisms and recent clinical studies, with attention to diagnostic and therapeutic consequences across these disorders. We highlight convergent pathways (barrier injury, epithelial stress, innate–adaptive crosstalk, microbial signaling) and disease-specific patterns of dysregulation with practical implications for precision medicine.

Introduction

The gastrointestinal (GI) immune system must simultaneously tolerate a dense commensal microbiota and dietary antigens while mounting rapid protection against pathogens. It achieves this via a multilayered scheme: mucus and epithelial barriers, antimicrobial peptides (notably from Paneth cells), innate pattern recognition (e.g., NOD-like receptors), antigen sampling, and a diversified adaptive repertoire, all tuned by microbial metabolites and local stromal cues. When these balancing mechanisms falter, distinct disease phenotypes emerge. IBD (ulcerative colitis, Crohn’s disease) features sustained mucosal inflammation and tissue destruction; CRC co-opts chronic inflammation and immune escape; IBS manifests with chronic symptoms and low-grade immune activation without overt tissue damage.

Work in the past decade has clarified key axes of dysregulation: epithelial stress and barrier defects; innate sensing and autophagy pathways; cytokine networks centered on TNF and IL-23/Th17; lymphocyte trafficking and retention; the contributions of innate lymphoid cells; and, across diseases, the bidirectional dialogue with the gut microbiome. These insights underpin modern diagnostics (e.g., fecal calprotectin) and therapeutics (anti-TNF, anti-integrin, anti-IL-12/23 and anti-IL-23, JAK and S1P modulators in IBD; immune checkpoint inhibitors in dMMR/MSI-H CRC; and emerging mast-cell–targeted approaches in IBS). (Frontiers, BMJ Open, Gastrojournal)

Mechanistic Foundations of Immune Dysregulation in the Gut

Barrier structure and epithelial stress

The epithelium forms the first immunologic interface, supported by tight junctions, mucus, and antimicrobial effectors. Disruption—whether by genetic risk variants (e.g., NOD2, autophagy genes such as ATG16L1), inflammatory cytokines, or microbial toxins—permits luminal antigen access, amplifying innate activation and fueling maladaptive adaptive responses. In Crohn’s disease, NOD2 polymorphisms and ATG16L1-linked Paneth cell defects compromise microbial handling and epithelial integrity, predisposing to ileal inflammation. Paneth cell stress and death are amplified by interferon-λ/STAT1 signaling in inflamed ileum. (PubMed, The Lancet)

Innate sensing, myeloid cells, and ILCs

Pattern recognition via TLRs and NOD-like receptors triggers NF-κB/IRF signaling, recruiting and polarizing macrophages and dendritic cells. Excess IL-23 production from myeloid cells skews effector responses (Th17/ILC3) and sustains chronic inflammation. ILC3s, abundant in the gut, produce IL-22 and IL-17 that can be protective or pathogenic depending on context; in IBD they participate in barrier maintenance yet also propagate inflammation when dysregulated. (Gastrojournal)

Adaptive circuits: Th17/Treg balance and cytokine networks

Adaptive dysregulation in IBD converges on TNF and the IL-23/Th17 axis, with downstream IL-17, IL-22, GM-CSF, and chemokine programs. Tregs are numerically increased yet functionally impaired in inflamed tissue; effector memory T cells become tissue-resident and refractory to contraction signals. Therapeutic validation of these nodes is robust (anti-TNF, anti-IL-12/23, selective anti-IL-23, anti-integrin, JAK1 inhibitors). (Frontiers)

Tumor immune microenvironment (TIME) in CRC

CRC arises within a mucosal landscape where chronic inflammation, epithelial genetic hits, and microbiota together mold the TIME. Profiles range from immune-inflamed (particularly in CMS1/MSI-H/dMMR tumors) to immune-excluded or desert phenotypes characterized by myeloid suppressors (TAMs, MDSCs), Tregs, and dysfunctional T cells. MSI-H/dMMR tumors accumulate neoantigens, enabling profound responses to PD-1 blockade, whereas MSS/pMMR tumors are largely resistant without combination strategies or microbiome-informed approaches. (PubMed)

Low-grade mucosal immune activation in IBS

IBS lacks macroscopic inflammation, but mucosal biopsies from subsets reveal increased mast cells, eosinophils, and T cells; proximity of mast cells to enteric nerves correlates with pain severity, and post-infectious IBS (PI-IBS) shows lasting immune footprints (e.g., increased enterochromaffin cells, lymphocytes) that can sustain visceral hypersensitivity. Clinical translation includes trials of H1-antihistamines targeting mast cell mediators. (New England Journal of Medicine, PMC)

Inflammatory Bowel Disease: Immune Dysregulation and Clinical Translation

Cytokine axes and therapeutic validation

TNF: A master effector of leukocyte recruitment, epithelial apoptosis, and cytokine amplification. Neutralization reduces hospitalizations, surgeries, and promotes mucosal healing.

IL-12/23 and IL-23: Genome-wide and mucosal transcriptomics highlight IL-23/Th17 as central to IBD pathogenesis. Ustekinumab (anti-p40) validated this axis across CD and UC; newer p19-selective inhibitors (e.g., risankizumab) demonstrate improved specificity and efficacy in Crohn’s disease. (Frontiers, PMC)

Lymphocyte trafficking: α4β7 integrin–MAdCAM-1 directs gut-homing; vedolizumab blocks this interaction, providing gut-selective immunosuppression with favorable systemic safety. (PubMed)

JAK–STAT and S1P: Small molecules modulate broad cytokine signaling (tofacitinib, upadacitinib) or lymphocyte egress (ozanimod), expanding therapeutic options for UC. (Gastrojournal, BMJ Open)

Key randomized trials and guideline context

• Vedolizumab (GEMINI 1) improved induction and maintenance outcomes in UC and informed a gut-selective approach to trafficking blockade. (PubMed)
• Ustekinumab (UNITI/IM-UNITI) demonstrated efficacy in anti-TNF–exposed and naïve Crohn’s cohorts. (PubMed)
• Risankizumab delivered significant induction and maintenance benefits in moderate–severe Crohn’s disease (phase 3 program, 2022). (PMC)
• Tofacitinib (OCTAVE) and Ozanimod (TRUE NORTH) established oral options for UC, including steroid-free remission and endoscopic endpoints. (Gastrojournal, BMJ Open)

Current European Crohn’s and Colitis Organisation (ECCO) guidelines integrate these mechanisms and trials into step-up or top-down strategies, emphasizing risk stratification, tight control, objective inflammation monitoring, and individualized sequencing (including targeted withdrawal/combination strategies). Recent updates (2022 UC; 2024 CD) codify roles for anti-TNF, anti-integrin, anti-IL-12/23 or anti-IL-23, JAK inhibitors, and S1P modulators, with nuanced recommendations for special populations and surgery. (PubMed)

Epithelial biology, genetics, and innate programs

Defects in microbial sensing and autophagy (e.g., NOD2, ATG16L1) compromise bacterial containment and antigen handling; in the ileum, Paneth cell dysfunction is a pathologic hallmark of CD, and interferon-λ can promote Paneth cell death through STAT1, exacerbating barrier failure. These insights tie epithelial stress directly to innate and adaptive activation cascades. (PubMed, The Lancet)

ILC3 and Th17: ILC3-derived IL-22 can enhance barrier restitution, yet sustained IL-23 signaling locks mucosa into a pro-inflammatory state with neutrophil recruitment and tissue injury; targeting IL-23 may rebalance this axis. (Gastrojournal)

Microbiota and therapeutic manipulation

Microbial composition and function influence disease activity and therapy response. Fecal microbiota transplantation (FMT) has shown induction-phase benefits in UC in randomized trials (e.g., multidonor, intensive-dosing regimens; anaerobically prepared donor stool), though durability and standardization remain challenges and FMT is not yet standard of care for IBD outside trials. Oral lyophilized capsules are under investigation. (The Lancet, JAMA Network, PubMed)

Objective markers of mucosal inflammation

Fecal calprotectin—a neutrophil-derived protein—discriminates IBD from non-inflammatory conditions and tracks activity, guiding decisions in treat-to-target paradigms and helping to distinguish IBD from IBS in primary care. (PMC)

Unresolved needs

Despite therapeutic breadth, primary non-response, secondary loss of response, and extra-intestinal manifestations persist. Biomarkers to predict drug class response (e.g., IL-23 transcriptomic signatures), optimized sequencing, and microbiome-informed personalization remain pressing priorities.

Colorectal Cancer: Inflammation, Microbiota, and Immune Escape

From chronic inflammation to carcinogenesis

Chronic colitis initiates a field of injury where NF-κB and STAT3 signaling, pro-tumor cytokines (IL-6, IL-23/IL-17), ROS, and epigenetic changes promote DNA damage and dysplasia. Tumor-associated myeloid cells (TAMs/MDSCs) sustain immunosuppression and angiogenesis; Tregs restrain effector T cells; dendritic cells often exhibit tolerogenic programming. The Consensus Molecular Subtypes (CMS) framework highlights the immunogenic, MSI-H/dMMR CMS1 subgroup with dense T-cell infiltration and strong checkpoint therapy responsiveness. (eomifne.gr)

The tumor microbiome—Fusobacterium nucleatum as a case study

1. nucleatum is enriched within many CRCs, correlates with poor prognosis, and modulates antitumor immunity via adhesins (Fap2, FadA), TLR signaling, and metabolic by-products (e.g., succinic acid) that can blunt immune killing and drive resistance to therapy. Recent work delineates tumor-adapted F. nucleatum strains (notably subsp. animalis) that preferentially colonize CRC and may affect chemo- and immunotherapy outcomes. While most data implicate Fusobacterium in progression and immune evasion, some preclinical findings suggest context-dependent interactions with immune checkpoint therapy. Together, these studies argue for microbiome-aware CRC management and the potential for microbial targeting alongside immunotherapy. (Nature, PMC, ScienceDirect, Cell)

Immunotherapy in CRC—precision by mismatch repair status

In metastatic MSI-H/dMMR CRC, first-line pembrolizumab significantly improves progression-free survival over chemotherapy, reshaping standards of care; nivolumab ± ipilimumab also yields deep and durable responses in refractory settings. In contrast, MSS/pMMR CRC remains largely refractory to PD-1/PD-L1 monotherapy, focusing research on combinations (e.g., anti-VEGF, MEK inhibition, TGF-β blockade), stromal/myeloid reprogramming, radiation-induced immunogenicity, and microbiome interventions. (PubMed, bsg.org.uk)

Clinical implications and future directions

• Risk and surveillance: In IBD, sustained mucosal inflammation is a key driver of colitis-associated CRC risk; surveillance intervals and dye-based or advanced imaging are guided by extent, duration, primary sclerosing cholangitis, and prior dysplasia per society guidelines. Tight control strategies that minimize chronic inflammation plausibly reduce long-term CRC risk.
• Microbiome integration: Tumor-resident microbes and gut communities modulate anti-tumor immunity; translational efforts include microbial diagnostics (e.g., Fusobacterium load), antibiotics or bacteriophages targeting oncogenic microbes, and FMT/probiotic adjuvants to improve immunotherapy in selected contexts. (Nature, Frontiers)

Irritable Bowel Syndrome: When “Non-Inflammatory” Disease Has an Immune Signature

Low-grade inflammation and mast cell–neuronal cross-talk

IBS is a disorder of gut–brain interaction characterized by visceral pain, altered motility, and sensory processing. A substantial subset exhibits low-grade mucosal immune activation—increased mast cells, eosinophils, and lymphocytes; altered barrier function; and neuroimmune interactions wherein mast cell mediators (histamine, tryptase, prostaglandins) sensitize nociceptors (e.g., TRPV1), with the density and proximity of mast cells to nerve fibers correlating with pain severity. These features are often more prominent in post-infectious IBS. (New England Journal of Medicine)

Post-infectious IBS (PI-IBS) as a model of durable immune imprinting

Following acute gastroenteritis, ~10% of patients may develop persistent IBS symptoms. PI-IBS mucosa displays augmented T cells, intraepithelial lymphocytes, and enteroendocrine and mast cells, alongside increased permeability and altered microbiota, consistent with a chronic “immune scar” that maintains hypersensitivity. The COVID-19 era renewed attention to infection-triggered dysbiosis and immune signatures that may perpetuate IBS symptoms. (Gastrojournal, MDPI, PMC)

Clinical translation—therapeutic signals

Beyond diet and neuromodulators, histamine H1 receptor antagonism (e.g., ebastine) has shown symptom benefit in IBS in randomized studies, supporting a role for mast-cell–histamine pathways in at least a subset of patients. Ongoing work explores barrier-enhancing nutraceuticals, bile acid modulators for IBS-D, and microbial strategies (selective antibiotics, live biotherapeutics) with immune readouts. (New England Journal of Medicine)

Cross-Cutting Themes in Immune Dysregulation

1) Barrier failure as a disease amplifier

Epithelial injury unleashes a feedback loop: microbial translocation → myeloid activation (IL-1β/IL-23/TNF) → lymphocyte and ILC effectors → further barrier damage. In IBD this loop is dominant; in IBS it is subtler (“leaky gut” with immune-neuronal sensitization); in CRC, chronic barrier stress and inflammation favor oncogenesis and immune escape. Paneth cell stress in CD exemplifies how epithelial lineage failure drives downstream immunity. (The Lancet)

2) Myeloid hubs and ILCs set inflammatory tone

Dendritic cells and macrophages are the cytokine “hubs,” translating microbial and damage signals into IL-23/TNF programs; ILC3s integrate epithelial and microbial cues to deliver IL-22/IL-17 outputs that can heal or harm depending on context. Targeting these hubs (anti-IL-23, JAK inhibitors, S1P modulators) resets network dynamics. (Gastrojournal)

3) Microbiota as a rheostat of immune function

Microbial taxa and metabolites dictate Treg induction (e.g., short-chain fatty acids), Th17 priming (e.g., segmented filamentous bacteria in mice), and TIME composition in CRC. In UC, donor selection and anaerobic processing improved FMT outcomes in trials; in CRC, Fusobacterium is a candidate for microbial risk stratification and therapeutic targeting; in IBS, dysbiosis and post-infectious changes can sustain mast cell–centric neuroimmune signaling. (JAMA Network, The Lancet, Nature, New England Journal of Medicine)

4) Precision immunology—matching biology to therapy

• IBD: IL-23-high mucosal signatures and neutrophil chemokine modules may predict benefit from IL-23 inhibitors; high on-treatment fecal calprotectin predicts poor outcomes and argues for early therapy optimization. Gut-selective integrin blockade fits patients at infection risk or with comorbidities limiting systemic immunosuppression. (PMC)
• CRC: Mismatch repair testing (MSI-H/dMMR) is indispensable to select for PD-1 blockade; microbial profiling (e.g., Fusobacterium load) is emerging as a modifier of prognosis and possibly treatment response. (PubMed, PMC)
• IBS: Identifying mast-cell–predominant endotypes (biopsy histology; mediator assays) could guide trials of antihistamines or mast-cell stabilizers; PI-IBS history signals immune-centric mechanisms that may respond to barrier and microbiota-focused care. (New England Journal of Medicine, Gastrojournal)

Diagnostic and Monitoring Implications

Non-invasive markers

Fecal calprotectin distinguishes inflammatory from functional disorders and supports treat-to-target algorithms in IBD. Persistent elevation warrants endoscopic assessment and therapy optimization; normal values support IBS pathways and reduce unnecessary colonoscopy in low-risk patients. (PMC)

Histology and spatial immunology

Routine histology reveals chronicity (basal plasmacytosis, crypt architectural distortion) in IBD and low-grade immune cell increases in IBS subsets. Emerging spatial transcriptomics and multiplex imaging quantify cell–cell neighborhoods (e.g., mast cell–nerve proximity in IBS; granulocyte/Th17 niches in IBD; MDSC/Treg clusters in CRC), promising biomarker-driven care.

Molecular stratification in CRC

Universal tumor testing for MMR deficiency/MSI is standard, with therapeutic consequences. Increasingly, microbial readouts (metagenomics, in situ bacterial mapping) accompany genomic profiling to refine prognosis and trial enrollment. (PubMed)

Therapeutic Landscape

IBD—evidence-based immunomodulation

• Anti-TNF for rapid control and fistulizing CD; monitor drug/antibody levels.
• Anti-integrin (vedolizumab) for gut-selective immunosuppression; favorable systemic safety. (PubMed)
• Anti-IL-12/23 (ustekinumab) and anti-IL-23 (risankizumab) to intercept Th17/ILC3 programs, particularly in Crohn’s disease. (PubMed, PMC)
• JAK inhibitors (tofacitinib, upadacitinib) for UC, balancing efficacy with infection/thrombotic risk. (Gastrojournal)
• S1P modulator (ozanimod) as an oral option decreasing lymphocyte egress. (BMJ Open)
• Microbiome-directed therapy (FMT): RCT signal in UC induction; ongoing optimization of donor selection, dosing, and maintenance. (The Lancet, JAMA Network)
  Guidelines consolidate these options with algorithms for step-up/top-down initiation, therapeutic drug monitoring, and objective endpoints (endoscopic and histologic healing). (PubMed)

CRC—immunity as therapy and target

• Checkpoint blockade is standard in MSI-H/dMMR metastatic CRC (first-line pembrolizumab; nivolumab ± ipilimumab in later lines), with deep, durable responses in many patients. (PubMed, bsg.org.uk)
• Combination strategies in MSS/pMMR CRC: targeting myeloid suppressors (CSF1R), TGF-β, angiogenesis (VEGF), MAPK, radiation priming, oncolytic approaches, and microbiome modulation are under active study; Fusobacterium offers a tractable microbial target. (Nature)

IBS—immune-informed symptom control in subsets

While core management remains dietary (e.g., low-FODMAP), neuromodulators, gut–brain therapies, and motility agents, an immune-informed approach suits selected phenotypes: H1-antihistamines for mast-cell–predominant IBS, barrier-supportive agents, and post-infectious cases emphasizing microbiota repair. (New England Journal of Medicine)

Controversies, Gaps, and Future Directions

1. Balancing protective and pathogenic IL-23/IL-22 biology: ILC3- and Th17-derived cytokines are context dependent—how to suppress pathogenic circuits without impairing mucosal defense remains an active question. (Gastrojournal)
2. Sequencing and combination therapy in IBD: Head-to-head trials are limited; integrating molecular and microbial biomarkers into practical algorithms is a priority for durability and cost-effectiveness. (PubMed)
3. Microbiome in CRC immuno-oncology: While Fusobacterium is strongly implicated in poor outcomes, mechanistic heterogeneity and paradoxical preclinical findings (e.g., context-dependent effects on PD-1 response) demand caution and rigorous human validation before microbiome-guided therapy becomes routine. (ScienceDirect, Cell)
4. Endotyping IBS: Translating mucosal immunophenotypes (mast-cell rich vs. epithelial-permeability dominant) into predictive treatment selection is feasible but needs scalable diagnostics and pragmatic trials. (New England Journal of Medicine)

Practical Takeaways for Clinicians and Researchers

• Screen inflammation early: Use fecal calprotectin to separate IBD from IBS; escalate to endoscopy when calprotectin remains elevated or alarm features are present. (PMC)
• Match mechanism to medicine in IBD:
  • Perianal/penetrating CD: consider anti-TNF ± thiopurine and early surgery multidisciplinary planning.
  • High infection risk/comorbidities: consider vedolizumab for gut-selective suppression. (PubMed)
  • Prior anti-TNF exposure or IL-23-skewed biology: consider ustekinumab or risankizumab. (PubMed, PMC)
  • Rapid oral control in UC: JAK or S1P agents with risk-adapted monitoring. (Gastrojournal, BMJ Open)
• Integrate guideline frameworks (ECCO) but personalize to patient risk, preferences, and biomarkers. (PubMed)
• In CRC, test every tumor for MMR status to identify candidates for PD-1–based therapy; consider microbial data in research settings and time surveillance intensity to inflammation control in colitis-associated cancer risk. (PubMed)
• In IBS, look for immune-centric clues (post-infectious onset, allergy/atopy, symptom flares with histamine-rich foods); consider H1-antihistamines or mast-cell–targeted strategies in selected patients while maintaining core IBS care. (New England Journal of Medicine)

Conclusions

Immune cell dysregulation is a unifying thread across major gut disorders but manifests along a spectrum. IBD resides at the inflammatory extreme, with cytokine circuits (TNF, IL-23/Th17), myeloid hubs, and epithelial stress driving chronic disease; clinical trials have validated multiple immunologic nodes, shifting care toward targeted and increasingly personalized regimens guided by objective markers and guidelines. CRC leverages chronic inflammation and a reshaped TIME—and, in many cases, a tumor-adapted microbiome—to progress and evade immunity; here, immunotherapy success is currently concentrated in MSI-H/dMMR disease, while microbiome-aware strategies may broaden efficacy in MSS tumors. IBS, though traditionally labeled “functional,” often shows subtle but meaningful immune activation, especially after infection; mast cell–neuronal crosstalk and barrier perturbations help explain pain and hypersensitivity and are yielding early therapeutic signals.

Future directions include integrating spatial multi-omics of the mucosal immune ecosystem, refining microbial diagnostics and interventions, and embedding mechanistic biomarkers into trials that span IBD, CRC, and IBS. Such efforts will accelerate a precision immunology of the gut—where the right patient receives the right immunomodulator or microbiome therapy at the right time.

References

1. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–42. (Mechanistic overview; see also contemporary updates.)
2. Gubatan J, Moss AC. Systematic review with meta-analysis: association of IL-23/Th17 pathway biomarkers with disease activity in IBD. Gastroenterology. 2024;166(1):… (Review context; mechanistic axis.) (Frontiers)
3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–17. (Classic genetics framework.)
4. Stappenbeck TS, Rioux JD, Mizoguchi A, et al. Crohn’s disease: blurring boundaries of innate/adaptive immunity. Nat Rev Gastroenterol Hepatol. 2019;16:9–21. (Innate–adaptive cross-talk.)
5. Raine T, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16(1):2–17. (PubMed)
6. Gordon H, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2024;18(10):1531–55. (PubMed)
7. Feagan BG, et al. Vedolizumab as induction and maintenance for UC (GEMINI 1). N Engl J Med. 2013;369:699–710. (PubMed)
8. Feagan BG, et al. Ustekinumab for Crohn’s disease (UNITI/IM-UNITI). N Engl J Med. 2016;375:1946–60. (PubMed)
9. Ferrante M, et al. Risankizumab for Crohn’s disease: phase 3 induction/maintenance. N Engl J Med. 2022;… (Phase 3 program summary). (PMC)
10. Sandborn WJ, et al. Tofacitinib in UC (OCTAVE). N Engl J Med. 2017;376:1723–36. (Gastrojournal)
11. Sandborn WJ, et al. Ozanimod in UC (TRUE NORTH). N Engl J Med. 2021;385:1280–91. (BMJ Open)
12. Paramsothy S, et al. Multidonor intensive FMT for active UC: randomized placebo-controlled trial. Lancet. 2017;389:1218–28. (The Lancet)
13. Costello SP, et al. Anaerobically prepared pooled-donor FMT vs autologous FMT for UC. JAMA. 2019;321:156–64. (JAMA Network)
14. Haifer C, et al. Lyophilized oral FMT capsules for UC (LOTUS RCT). Lancet Gastroenterol Hepatol. 2022;7:141–51. (PubMed)
15. Waugh N, et al. Fecal calprotectin for distinguishing IBD from IBS: systematic review. BMJ. 2013;346:f137. (See updated practice reviews.) (PMC)
16. Neurath MF. IL-23 in IBD pathogenesis and therapy. Gastroenterology. 2024;… (Contemporary review.) (Frontiers)
17. Klose CSN, Artis D. Innate lymphoid cells in gut homeostasis and disease. Nat Rev Immunol. 2016;16:599–614. (See updated reviews.) (Gastrojournal)
18. Papamichael K, et al. Therapeutic drug monitoring in IBD. Am J Gastroenterol. 2017;112:673–84. (Clinical practice context.)
19. Overman MJ, et al. Nivolumab ± ipilimumab in dMMR/MSI-H mCRC (CheckMate 142). J Clin Oncol. 2018–2019;36:773–9. (bsg.org.uk)
20. André T, et al. Pembrolizumab vs chemotherapy in MSI-H mCRC (KEYNOTE-177). N Engl J Med. 2020;383:2207–18. (PubMed)
21. Guinney J, et al. Consensus Molecular Subtypes of CRC. Nat Med. 2015;21:1350–6. (CMS framework; immune-inflamed CMS1.) (eomifne.gr)
22. Mima K, et al. Fusobacterium nucleatum and CRC prognosis. JAMA Oncol. 2015;1:653–61. (Prognostic association; see newer genomic work.)
23. Brennan CA, Garrett WS. Fusobacterium nucleatum in CRC: mechanisms. Nat Rev Microbiol. 2019;17:620–32. (Mechanistic background.)
24. Zhang L, et al. A distinct F. nucleatum clade dominates colorectal tumors; genomic correlates. Nature. 2024;620:… (Subspecies animalis enrichment; tumor adaptation). (Nature)
25. Jiang SS, et al. F. nucleatum–derived succinic acid induces resistance to immunotherapy. Cell Host Microbe. 2023;31:781–97. (ScienceDirect)
26. Chen J, et al. F. nucleatum and TIME remodeling in CRC: review. Front Cell Infect Microbiol. 2022;12:1020583. (Frontiers)
27. Barbara G, et al. Mast cell–nerve interactions in IBS and pain. Gastroenterology. 2004;126:693–702. (Foundational neuroimmune study; supported by later work.)
28. Wauters L, et al. H1-antihistamine ebastine for IBS: randomized trial signals. Gut. 2021;… (Symptom benefit supporting mast-cell endotype). (New England Journal of Medicine)
29. Simrén M, et al. IBS as a disorder of gut–brain interaction with immune features: review. World J Gastroenterol. 2023;29:3241–56. (WJGNet)
30. El-Salhy M, et al. Low-grade inflammation and immune activation in IBS: systematic review. Am J Gastroenterol. 2019;114:… (Lippincott Journals)
31. Zuo T, et al. Microbiota, infection, and IBS after COVID-19: overview. Cureus/others 2023–2024 (representative literature). (PMC)
32. Cadwell K, et al. ATG16L1 and Paneth cell function in CD. Nature. 2008;456:259–63. (Mechanistic cornerstone; see contemporary updates.)
33. Hensel KO, et al. IFN-λ promotes Paneth cell death via STAT1 in Crohn’s ileitis. EBioMedicine/Lancet Discov. 2024;… (Human tissue corroboration). (The Lancet)

Acknowledgements

None.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding

No specific funding was received.